Back
Fulcrum Therapeutics, Inc. 10K Form
Sell
48
FULC
Fulcrum Therapeutics, Inc.
Last Price:
$12.06
Seasonality Move:
0.09%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive FULC News And Ratings
See the #1 stock for the next 7 days that we like better than FULC
FULC Financial Statistics
Sales & Book Value
| Annual Sales: | $80M |
|---|---|
| Cash Flow: | $-14.3M |
| Price / Cash Flow: | 60.7 |
| Annual Sales: | $3.67 |
| Price / Book: | 3.22 |
Profitability
| EPS (TTM): | -1.17920 |
|---|---|
| Net Income (TTM): | $-71.1M |
| Gross Margin: | $78.4M |
| Return on Equity: | -31.15% |
| Return on Assets: | -29% |
Fulcrum Therapeutics, Inc. Earnings Forecast
Key Fulcrum Therapeutics, Inc. Financial Ratios
-
The Gross Profit Margin over the past 8 years for FULC is 98.01%.
-
The Selling, General & Administrative Expenses for FULC have been equal to 45.56% of Gross Profit Margin.
-
The Research & Development expenses have been 77.24% of Revenue.
-
The Net Earning history of FULC is -12.16% of Total Revenues.
-
Per Share Earnings over the last 8 years have been positive in 4 years.
Fulcrum Therapeutics, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Pharmaceuticals |
| Sector: | Health Care |
| Current Symbol: | FULC |
| CUSIP: | 359616 |
| Website: | fulcrumtx.com |
Debt
| Debt-to-Equity Ratio: | 0.04 |
|---|---|
| Current Ratio: | 17.7 |
| Quick Ratio: | 17.25 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
FULC Technical Analysis vs Fundamental Analysis
Sell
48
Fulcrum Therapeutics, Inc. (FULC)
is a Sell
Is Fulcrum Therapeutics, Inc. a Buy or a Sell?
-
Fulcrum Therapeutics, Inc. stock is rated a SellThe current Fulcrum Therapeutics, Inc. [FULC] share price is $11.79. The Score for FULC is 48, which is 4% below its historic median score of 50, and infers higher risk than normal.